Q32 Bio (QTTB) Shares Soar 60% After Positive Alopecia Treatment Trial Results
Q32 Bio (QTTB) stock soared 60% after bempikibart achieved primary endpoint in Phase 2a alopecia trial, showing 35.3% SALT score reduction with clean safety. The post Q32 Bio (QTTB) Shares Soar 60%…
Read the full articleYou might also wanna read
Q32 Bio stock soared after its alopecia drug cleared a key clinical bar
The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-dire
Quartz·2d ago
Why Q32 Bio Stock Skyrocketed Today
The biotech is advancing a potential treatment for a common autoimmune disease.
Bars·3d ago
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup
Corcept Therapeutics (CORT) shows strong growth with 12.2% revenue growth, zero debt, and accelerating EPS forecasts. The stock is near a 52
ChartMill·5d ago
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
GuruFocus·3d ago
Q32 Bio (QTTB) Launches $200M Public Offering to Fund Clinical Development
Related Stocks: QTTB
GuruFocus·1d ago
New drug data could lift shares of this biotechnology stock, Truist says
Biogen could see more upside if it publishes positive results from recent trials linked to kidney and Alzheimer's treatments, ...
cnbc.com·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.